A new company with plans to evolve into a national network of outpatient radiation-oncology centers was formed through a partnership with two leading providers of cancer-treatment services in the Southeast U.S., officials announced last week.
Radiation Oncology Services of America, Nashville, was started by Atlanta Oncology Associates, which has eight treatment centers in Georgia and the Florida Panhandle; and Cancer Care Centers, which has three treatment facilities in Tennessee.
The two founding companies, which will include 18 radiation oncologists, created the firm in a financial partnership with MedCare Investment Fund III, a private-equity firm in San Antonio.
No financial details were released, said Rosemary Plorin, a spokeswoman for the new cancer-treatment company.
Dale McCord, a physician who is president and chief executive officer of Atlanta Oncology Associates, said he expects the company to raise the bar for everyone.
By focusing on providing quality outcomes driven by evidence-based care, ROSA will share the knowledge and best practices of leaders in the radiation-oncology field across a national network of physician providers, he said in a written statement.
All of the centers affiliated with the company offer state-of-the-art services, including intensity modulated radiation therapy, image-guided radiation therapy and high-dose brachytherapy.
The new companys board of directors is chaired by Harry Jacobson, a physician. He is vice chancellor for health affairs at Vanderbilt University in Nashville and a co-founder of Renal Care Group, a doctor-oriented dialysis-services company that was acquired earlier this year for $3.5 billion by Bad Homburg, Germany-based Fresenius Medical Care, the worlds largest provider of dialysis products and services.
Jacobson also is a member of the advisory board to the new Health Care Solutions Group, a not-for-profit quality improvement collaborative backed by the Nashville Health Care Council and Vanderbilt University Medical Center.
Plorin said the organizations roles did not create any potential conflicts for Jacobson, whose roles in all the separate groups are public.
Doctor Jacobson is mindful of his responsibilities to various organizations, and he is confident that there is no conflict between any of those interests, Plorin said. ROSA has vetted that.
Officials said the new firm will lend its expertise in ambulatory healthcare services to build its business in the highly competitive U.S. radiation-therapy market, which is estimated at $7 billion a year. The new company will join a mix of about 2,000 free-standing or hospital-based centers across the nation that now offer radiation therapy.